文献速递系统性红斑狼疮

基于转录组分子特征深度分层以实现系统性红斑狼疮患者的精准治疗

Deep stratification by transcriptome molecular characters for precision treatment of patients with systemic lupus erythematosus.
PubMed 文献 · Rheumatology (Oxford) · 2023-01-01

研究整合6个微阵列数据集,构建1046例SLE患者和86名健康对照的外周血单核细胞转录组汇编,基于278个上调差异表达基因将SLE分为3个亚型,各具不同分子和细胞特征,并与临床特征及治疗反应相关。

要点

  • 基于278个上调差异表达基因将SLE分为A、B、C三个亚型,各具不同分子和细胞特征。
  • A亚型为NE驱动型,中性粒细胞活化相关通路显著激活;B亚型为IFN驱动型,淋巴细胞和IFN相关通路更富集。
  • C亚型为NE-IFN双驱动型,是最严重亚型,与临床特征密切相关并可预测治疗反应。

核心结论

  • 研究构建了迄今最大的SLE转录组汇编用于深度分层,结果可指导未来SLE分子诊断设计和分层治疗开发。

研究设计与样本

  • 研究整合6个微阵列数据集,构建覆盖13689个基因的转录组汇编,样本为1046例SLE患者和86名健康对照的外周血单核细胞。
  • 对上调差异表达基因进行功能和网络分析,采用无监督聚类对样本分组以识别患者亚型。
  • 通过相同方法对6个整合RNA测序数据集进行分层以评估聚类稳定性,并应用Xgboost分类器于独立数据集识别与治疗结局相关的因素。

主要发现

  • 基于278个上调差异表达基因,SLE患者被分为A、B、C三个亚型,各具不同分子和细胞特征。
  • A亚型(NE驱动型)中性粒细胞活化相关通路显著激活,B亚型(IFN驱动型)淋巴细胞和IFN相关通路更富集。
  • C亚型(NE-IFN双驱动型)为最严重亚型,与NE驱动型和IFN驱动型共享功能机制,与临床特征密切相关并可预测治疗反应。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To leverage the high clinical heterogeneity of systemic lupus erythematosus (SLE), we developed and validated a new stratification scheme by integrating genome-scale transcriptomic profiles to identify patient subtypes sharing similar transcriptomic markers and drug targets. METHODS: A normalized compendium of transcription profiles was created from peripheral blood mononuclear cells (PBMCs) of 1046 SLE patients and 86 healthy controls (HCs), covering an intersection of 13 689 genes from six microarray datasets. Upregulated differentially expressed genes were subjected to functional and network analysis in which samples were grouped using unsupervised clustering to identify patient subtypes. Then, clustering stability was evaluated by the stratification of six integrated RNA-sequencing datasets using the same method. Finally, the Xgboost classifier was applied to the independent datasets to identify factors associated with treatment outcomes. RESULTS: Based on 278 upregulated DEGs of the transcript profiles, SLE patients were classified into three subtypes (subtype A-C) each with distinct molecular and cellular signatures. Neutrophil activation-related pathways were markedly activated in subtype A (named NE-driving), whereas lymphocyte and IFN-related pathways were more enriched in subtype B (IFN-driving). As the most severe subtype, subtype C [NE-IFN-dual-driving (Dual-driving)] shared functional mechanisms with both NE-driving and IFN-driving, which was closely associated with clinical features and could be used to predict the responses of treatment. CONCLUSION: We developed the largest cohesive SLE transcriptomic compendium for deep stratification using the most comprehensive microarray and RNA sequencing datasets to date. This result could guide future design of molecular diagnosis and the development of stratified therapy for SLE patients.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Qiao J, Zhang SX, Chang MJ, et al. Deep stratification by transcriptome molecular characters for precision treatment of patients with systemic lupus erythematosus. Rheumatology (Oxford). 2023. PMID: 36308437. doi:10.1093/rheumatology/keac625

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。